Coherus Oncology, Inc. (CHRS) Revenue 2016–2025
Coherus Oncology, Inc. (CHRS) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$42.2MFY2025 · since FY2016: $189.5M → $42.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $42.2M | +59.8% |
| FY2024 | $26.4M | -89.7% |
| FY2023 | $257.2M | +21.9% |
| FY2022 | $211.0M | -35.4% |
| FY2021 | $326.6M | -31.4% |
| FY2020 | $475.8M | +33.6% |
| FY2019 | $356.1M | — |
| FY2018 | $0 | -100.0% |
| FY2017 | $1.6M | -99.2% |
| FY2016 | $189.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice